When we incorporated Alvita in 2010, the goal was simple on paper and hard in practice: unite R&D, manufacturing, and regulatory expertise under one trusted partner, so pharma brands could stop stitching together fragmented vendors.

The milestones behind the number

• 2012 — Novagen manufacturing facility went live, adding WHO-GMP-grade capacity

• 2018 — Our first R&D center opened, cutting formulation-to-market timelines significantly

• 2020 — 24C Derma launched as our first domestic consumer brand

• 2022 — Team expanded past 70 multidisciplinary professionals spanning science, compliance, and market insight

Why this matters for partners

Crossing ₹100 crore in turnover isn’t just a finance milestone — it reflects 500+ successful registrations across 30+ countries and four continents, and it’s what lets us keep MOQs flexible for partners entering new markets with small validation batches.

We’re building toward the next decade with the same principle we started with: R&D, manufacturing, and regulatory should never be three separate vendors.